Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.42 |
| ▸ | KDR | P35968 | 14/20 | 0.42 |
| ▸ | MST1R | Q04912 | 10/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106737 | 0.87 | MET (0.45) | METKDRMST1RNTRK1KIT | |
| SCHEMBL1478770 | 0.83 | MET (0.42) | METKDRMST1R | |
| SCHEMBL15808535 | 0.83 | MET (0.43) | METKDRMST1RNTRK1KIT | |
| SCHEMBL3864631 | 0.82 | MET (0.46) | METKDRMST1RNTRK1KIT | |
| SCHEMBL16660462 | 0.79 | MAPT (0.37) | METKDRMST1R | |
| SCHEMBL106463 | 0.79 | MST1R (0.52) | METKDRMST1RNTRK1KIT | |
| SCHEMBL16660464 | 0.79 | MAPT (0.37) | METKDRMST1R | |
| SCHEMBL10172347 | 0.79 | MET (0.41) | METKDRMST1RNTRK1KIT | |
| SCHEMBL2534354 | 0.77 | MET (0.41) | METKDRMST1RNTRK1KIT | |
| SCHEMBL3563148 | 0.77 | MET (0.46) | METKDRMST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| EP-2426108-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MethylGene Inc. (CA) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | MET 1062/4885KDR 526/4885MST1R 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.